Inclusion Criteria:

- Adult patients, >/=18 years of age

- Moderate to severe active rheumatoid arthritis (DAS28>/=3.2) of >/=6 months duration

- Body weight
- Patients are on one or more non-biologic DMARDs at a stable dose for a period >/=8
weeks prior to study treatment

- Patients with inadequate clinical response to a stable dose of non-biologic DMARD

Exclusion Criteria:

- Major surgery (including joint surgery) within 8 weeks prior to screening or planned
major surgery within 6 months following randomization

- Rheumatic autoimmune disease other than rheumatoid arthritis, including systemic
lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis, or
significant systemic involvement secondary to rheumatoid arthritis

- History of or current inflammatory joint disease other than rheumatoid arthritis